EUVIMEDEUVIMED entdecken
Crossref

Radiometal Complexes as Pharmacokinetic Modifiers: A Potent 68 Ga-Labeled Gastrin-Releasing Peptide Receptor Antagonist Based on the Macrocyclic Metal Chelator NODIA-Me

Moritz-Valentin Schreck, Caroline Burgard, Alexander Schmidtke, Ina Hierlmeier, Tobias Stemler, Stephan Maus, Florian Rosar, Martin Jung, Andreas Speicher, Samer Ezziddin, Jason P Holland iD, Mark D Bartholomä iD

Molecular Pharmaceutics · 2023

DOI: 10.1021/acs.molpharmaceut.3c00852 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Pharmaceutics, 2023. Verfasst von Moritz-Valentin Schreck und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, Saarland University-Medical Center, Kirrbergerstrasse, D-66421 Homburg, Germany. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Breast Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 39 Literaturangaben. Gefördert von: Schweizerischer Nationalfonds zur F?rderung der Wissenschaftlichen Forschung, Deutsche Forschungsgemeinschaft, Universit?t des Saarlandes.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The gastrin-releasing peptide receptor (GRPr) is overexpressed in various cancer types including prostate and breast carcinomas, making it an attractive target for molecular imaging and therapy. In this work, we designed a novel GRPr antagonistic probe comprising metal chelator NODIA-Me. This 1,4,7-triazacyclononane-based chelator forms positively charged metal complexes due to its neutral methylimidazole arms. Because a positive charge at the N-terminus of GRPr conjugates is responsible for high receptor affinity as exemplified by the current gold standard DOTA-RM2, we investigated if a positively charged radiometal complex can be used as a pharmacokinetic modifier to also produce high-affinity GRPr conjugates. In this respect, the bioconjugate NODIA-Me-Ahx-JMV594 was prepared by a combination of solid-phase peptide synthesis and solution-based reactions in a 94% yield. Radiolabeling provided the 68Ga-labeled conjugate in radiochemical yields of >95% and radiochemical purities of >98% with mean molar activities of Am ∼17 MBq nmol-1. The competitive GRPr affinity of the metal-free and 69/71Ga-labeled conjugate was determined to be IC50 = 0.41 ± 0.06 and 1.45 ± 0.06 nM, respectively. The metal-free GRPr antagonist DOTA-RM2 and its corresponding 69/71Ga complex had IC50 values of 1.42 ± 0.07 and 0.98 ± 0.19 nM, respectively. Small-animal PET imaging of mice bearing GRPr(+) PC-3 tumors revealed high radioactivity accumulation in the tumors and in the pancreas as an organ with high levels of GRPr expression. These findings were corroborated by the corresponding ex vivo biodistribution data, in which the tumors and the pancreas exhibited the highest radioactivity accumulation. By coinjection of an excess of NODIA-Me-Ahx-JMV594, uptake in the tumors and GRPr(+) organs was significantly reduced, confirming specific receptor-mediated uptake. The estrogen receptor-positive tumor of a female breast cancer patient was clearly visualized by PET imaging using 68Ga-labeled NODIA-Me-Ahx-JMV594. To summarize, the positive charge at the N-terminus of the conjugate induced by the Ga(NODIA-Me) complex resulted in high GRPr affinity comparable to that of the potent antagonist DOTA-RM2. The conjugate NODIA-Me-Ahx-JMV594 is a promising probe for imaging of GRPr tumors that warrants further evaluation in larger patient cohorts as well as in combination with other radiometals.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic NeoplasmsBreast NeoplasmsMaleHumansAnimalsMiceReceptors, BombesinGallium RadioisotopesTissue DistributionCell Line, TumorChelating AgentsPositron-Emission TomographyBombesin

Stichwörter der Autor:innen

NODIA-Meantagonistbombesinbreast cancerchelatorgallium-68gastrin-releasing peptide receptorprostate cancer

Substanzen

Receptors, BombesinGallium RadioisotopesChelating AgentsBombesin

Autor:innen und Institutionen

  • Department of Nuclear Medicine, Saarland University-Medical Center, Kirrbergerstrasse, D-66421 Homburg, Germany.
  • Department of Medical Biochemistry and Molecular Biology, Saarland University, D-66421 Homburg, Germany.
  • Department of Organic Chemistry, Saarland University, D-66123 Saarbrücken, Germany.
  • Department of Chemistry, University of Zurich, Winterthurerstrasse 190, CH-8057 Zurich, Switzerland.

ORCID-Profile: Jason P Holland, Mark D Bartholomä

Förderung

  • Schweizerischer Nationalfonds zur F?rderung der Wissenschaftlichen Forschung
  • Deutsche Forschungsgemeinschaft
  • Universit?t des Saarlandes
  • Universit?t Z?rich

Zitieren

APA

Schreck, M. V., Burgard, C., Schmidtke, A., Hierlmeier, I., Stemler, T., Maus, S., Rosar, F., Jung, M., Speicher, A., Ezziddin, S., Holland, J. P., & Bartholomä, M. D. (2023). Radiometal Complexes as Pharmacokinetic Modifiers: A Potent 68 Ga-Labeled Gastrin-Releasing Peptide Receptor Antagonist Based on the Macrocyclic Metal Chelator NODIA-Me. Molecular Pharmaceutics. https://doi.org/10.1021/acs.molpharmaceut.3c00852

Vancouver

Schreck MV, Burgard C, Schmidtke A, Hierlmeier I, Stemler T, Maus S, et al. Radiometal Complexes as Pharmacokinetic Modifiers: A Potent 68 Ga-Labeled Gastrin-Releasing Peptide Receptor Antagonist Based on the Macrocyclic Metal Chelator NODIA-Me. Molecular Pharmaceutics. 2023. doi:10.1021/acs.molpharmaceut.3c00852

BibTeX
@article{Schreck2023,
  author = {Schreck, Moritz-Valentin and Burgard, Caroline and Schmidtke, Alexander and Hierlmeier, Ina and Stemler, Tobias and Maus, Stephan and Rosar, Florian and Jung, Martin and Speicher, Andreas and Ezziddin, Samer and Holland, Jason P and Bartholomä, Mark D},
  title = {Radiometal Complexes as Pharmacokinetic Modifiers: A Potent 68 Ga-Labeled Gastrin-Releasing Peptide Receptor Antagonist Based on the Macrocyclic Metal Chelator NODIA-Me},
  journal = {Molecular Pharmaceutics},
  year = {2023},
  doi = {10.1021/acs.molpharmaceut.3c00852}
}
Kostenlos starten →